Pancytopenia in a patient with scleroderma treated with infliximab

Menon, Yamini; Cucurull, E; Espinoza, Luis R.

doi:10.1093/rheumatology/keg341

Cited by 35 publications

(14 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Reported ocular complications include isolated cases of bilateral anterior optic neuropathy, 12 retrobulbar optic neuritis, 13 and infection of the eyelids by molluscum contagiosum. 14 At the systemic level, infliximab treatment has been associated with opportunistic infections (tuberculosis, 9,15 cryptococcosis, 16 pneumocystis 17 ), blood disorders (leukaemia, 18 pancytopenia 19 ), and skin disorders including neoplasias. 20 During 3 years of follow-up, we observed no local or systemic secondary effects associated with infliximab treatment, and patients complained of no further extraocular symptoms in the context of their disease.…”

Section: Discussionmentioning

confidence: 99%

Long-term treatment of refractory posterior uveitis with anti-TNFα (infliximab)

Benítez-del-Castillo

Martinez-de-la-Casa

Pato-Cour

et al. 2004

Eye

View full text Add to dashboard Cite

Purpose To evaluate the long-term efficacy and safety of infliximab as treatment for noninfectious posterior uveitis. Methods An open-label clinical trial including seven patients (12 eyes) with posterior uveitis refractory to conventional treatment regimens with corticosteroids and at least one immunosuppressive agent. Three intravenous doses of 5 mg/kg of infliximab were administered at weeks 0, 2, and 6. Infliximab infusion was repeated in patients undergoing a relapse of uveitis after initial remission. Improvement was defined as amelioration of visual acuity or disappearance of retinal exudates and/or haemorrhages, decreased macular oedema and/or vitreous opacities. All patients were followed up for at least 36 months.

show abstract

Section: Discussionmentioning

confidence: 99%

Long-term treatment of refractory posterior uveitis with anti-TNFα (infliximab)

Benítez-del-Castillo

Martinez-de-la-Casa

Pato-Cour

et al. 2004

Eye

View full text Add to dashboard Cite

show abstract

“…There have been few studies on the efficacy of infliximab and etanercept in these patients and the results are contradictory. Some authors report a positive effect [3, 4], whereas Menon et al [13] found that infliximab did not significantly improve the signs and symptoms of systemic sclerosis.…”

Section: Discussionmentioning

confidence: 99%

“…Fleishman et al [12] reported preliminary results supporting the use of infliximab in rheumatic diseases characterized by overproduction of TNFα, including scleroderma. On the contrary, Menon et al [13] reported unsuccessful infliximab treatment in a scleroderma patient with lung involvement.…”

Section: Introductionmentioning

confidence: 99%

Infliximab Treatment in a Patient with Systemic Sclerosis Associated with Lung Fibrosis and Pulmonary Hypertension

Bargagli

Galeazzi²,

Bellisai³

et al. 2005

Respiration

View full text Add to dashboard Cite

This is the first report of the efficacy of anti-TNFα treatment in a patient with lung fibrosis and pulmonary hypertension associated with advanced systemic sclerosis, refractory to conventional therapies. The patient was treated with infliximab (5 mg/kg) and methotrexate (10 mg/week) for 1 year. After 6 months of therapy, the echocardiogram showed a reduction in pulmonary pressure, confirmed after 1 year. During treatment, the patient’s quality of life improved significantly and high-resolution computed tomography of the chest, lung function tests and blood gas analysis remained stable. After 1 year, the patient decided to stop infliximab therapy (for family reasons related to the distance to our hospital). Lung function tests, pulmonary arterial pressures and blood gas analysis progressively worsened and the patient died 11 months later. Few open-label studies have been conducted on the efficacy of anti-TNFα therapy in patients with systemic sclerosis. Here we report our experience in a case of systemic sclerosis complicated by pulmonary fibrosis and hypertension. Infliximab treatment seemed effective, suggesting that controlled randomized trials to evaluate infliximab efficacy in these patients and to compare infliximab with other anti-TNFα treatments would be worthwhile.

show abstract

“…Se han descrito distintas discrasias hemáticas como pancitopenias y anemias aplásicas, algunas mortales, durante el tratamiento con agentes ATNFA (11)(12)(13).…”

Section: Hematológicasunclassified